Peptide education
Semaglutide
Ozempic · Wegovy · Rybelsus · GLP-1 receptor agonist
Semaglutide is a long-acting GLP-1 receptor agonist and the active ingredient behind three approved product names: Ozempic and Rybelsus for type 2 diabetes, Wegovy for weight management and related labeled uses. That approval record makes it one of the best-documented peptide drugs anywhere. It also makes semaglutide the most imitated name in the category, and the evidence only travels with the product: a regulator-reviewed pen or tablet carries the trial data, while a compounded vial, salt-form listing, or online seller carries the ingredient name.
The human evidence for semaglutide is as strong as peptide evidence gets, but it belongs to named products: Ozempic, Wegovy, Rybelsus. Strip the label off, with a compounded vial, a salt-form listing, or an online seller, and what remains is an ingredient name without the evidence attached.
Overview
Quick answer
The word "semaglutide" does not tell you product quality by itself. A branded FDA-reviewed pen or tablet, a compounded vial, a telehealth pharmacy product, a salt-form listing, and a research-use product can all use semaglutide language while differing in formulation, concentration, dose device, storage, oversight, adverse-event reporting, and legal status.
What is semaglutide?
A modified version of the gut hormone GLP-1, engineered to last about a week instead of minutes. Its labels describe what that design does: glucose-dependent insulin release, lower glucagon, slower early gastric emptying, and reduced appetite.
What is it approved for?
That depends on which product you name, because there is no single semaglutide indication. Ozempic injection, Ozempic tablets, and Rybelsus are diabetes products with product-specific cardiovascular-risk language. Wegovy covers chronic weight management, cardiovascular risk reduction, and MASH label language depending on the dosage form.
How should label schedules be read?
Each product has its own initiation and escalation schedule, and none of them convert into each other. Weekly injection milligrams, daily tablet milligrams, vial concentrations, and syringe units are separate product facts, not a conversion table.
What do clinics, forums, and online sellers talk about?
Weight loss, mostly: appetite, food noise, nausea, plateaus, insurance, shortages, and switching between GLP-1 drugs. The access questions run right behind: compounded vials, telehealth subscriptions, added ingredients, and whether a cheaper product is really the same as a branded pen or tablet.
Why do product, route, and supply channel matter?
Because they decide which evidence applies to what is actually in hand. Approved-product data are strong for the approved product; a compounded vial, a salt-form listing, or a research-use seller changes the dose-measurement, storage, and safety problem completely.
Reported practice
Commonly reported protocol
Compounded and telehealth GLP-1 programs. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Ozempic injection, Ozempic tablets, and Rybelsus tablets are semaglutide products with type 2 diabetes labeling. Their routes, dose escalation, strengths, and risk language are product-specific.
Wegovy is the semaglutide product label most directly tied to chronic weight management. Its injection schedule and tablet schedule are read from the Wegovy label, not copied from Ozempic or Rybelsus.
Semaglutide has high sequence homology to human GLP-1, binds the GLP-1 receptor, resists DPP-4 degradation, and has albumin-binding features that support a long half-life.
FDA has warned about compounded injectable semaglutide dosing errors, varying concentrations, salt forms, fraudulent compounded labels, and counterfeit Ozempic concerns.
Published online-market surveillance and compounded-product survey work describe nondelivery scams, probable substandard or falsified products, low-purity findings, endotoxin concerns, varied dosage forms, added ingredients, and limited storage or beyond-use-date disclosure.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Semaglutide has approved-product data for type 2 diabetes. | Yes, when the claim is tied to the approved diabetes products and the labeled populations. Ozempic injection and Rybelsus tablets both carry type 2 diabetes labeling, with product-specific routes, strengths, and escalation schedules. | GLP-1 receptor activation increases glucose-dependent insulin secretion, lowers glucagon secretion when glucose is high, and slows early post-meal gastric emptying. | Online discussions often blend blood-sugar control, appetite suppression, weight change, nausea, and insurance access. Those reports can mirror known label themes, but product-specific diabetes data and monitoring still come from the reviewed labels and trials. | Strong for approved diabetes products; it does not cover every oral, compounded, or research-use semaglutide product. |
| Semaglutide has approved-product data for weight management. | Strongest when the claim is about Wegovy and its labeled populations. Ozempic and Rybelsus may affect body weight, but Wegovy is the product label built around chronic weight management. | GLP-1 activity affects appetite, calorie intake, glucose handling, and gastric emptying. That biology fits the weight-management findings, but route and product still matter. | Clinics, telehealth ads, forums, and social posts frequently use Ozempic or semaglutide as shorthand for weight loss, including off-label conversations around diabetes products. | Strong for Wegovy-labeled use; weaker or off-label when the same statement is about Ozempic, Rybelsus, compounded vials, or online sellers. |
| A compounded semaglutide vial is basically the same as Wegovy or Ozempic. | FDA-reviewed labels describe specific products, strengths, devices, excipients, storage, indications, and safety language. FDA says compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. | The receptor target is only one part of the comparison. Concentration, salt form, sterility, endotoxin, fill accuracy, degradation, storage, beyond-use dating, and the dose-measuring device can all change risk. | Telehealth programs and online discussions often emphasize price, availability, custom strengths, "same active ingredient" language, and added ingredients. FDA and survey sources show why those claims need product-level scrutiny. | No. Ingredient-name overlap does not make a compounded vial equivalent to an FDA-reviewed pen, syringe, or tablet. |
| Compounded semaglutide dosing is easy to copy from a pen label. | FDA has received adverse-event reports tied to dosing errors with compounded injectable semaglutide, including errors from measuring doses, unit conversion, different concentrations, and health-professional miscalculation. | A prefilled pen and a multi-dose vial create different measurement problems. Milligrams, milliliters, units, concentration, and syringe type determine what dose is actually delivered. | Forum and telehealth discussions often focus on micro-adjustments, delayed escalation, restarting after side effects, or stretching supply. Those conversations can hide exactly the dose-device problem FDA warned about. | High risk. FDA's warning is specifically about compounded injectable products and dose-measurement mistakes. |
| Online semaglutide sellers can be judged by price or a COA. | Online-market testing found illegal-pharmacy traffic, nondelivery scams, probable substandard or falsified products, and quality problems. A COA or advertised purity value is not a verified medical supply chain. | Injectable or oral peptide quality depends on identity, potency, impurities, microbiology, endotoxin, degradation, labeling, and storage, not only receptor pharmacology. | Online discussions often focus on cost, shipping speed, advertised dose size, and whether a seller looks legitimate. Those signals are much weaker than regulated manufacturing and pharmacy verification. | Price, website polish, and a posted COA do not establish authenticity, potency, microbiology, endotoxin control, degradation, labeling, or storage conditions. |
Bottom line
Main takeaway
Ozempic is one semaglutide product with its own label, not a nickname for every GLP-1 medicine or every vial sold under the semaglutide name.
Work from the product, not the molecule: Ozempic, Wegovy, and Rybelsus each carry distinct labels, schedules, and studied populations. For compounded or online products, concentration, source, storage, and dose device decide whether any approved-product evidence is even relevant.
Current product labels and FDA GLP-1 pages define approved uses and schedules. The online-market and compounded-product literature documents quality failures, dosing errors, and counterfeits; it does not extend the approved evidence to those channels.
Identity
What it is
Semaglutide is a GLP-1 analog chemically tuned for longevity: 94% sequence homology to human GLP-1, with modifications that protect it from DPP-4 breakdown and bind it to albumin. The result is a hormone signal that lasts about a week, which is what makes once-weekly products possible.
It is discussed everywhere because it sits at the center of diabetes care, obesity medicine, cardiovascular-risk labeling, liver-disease labeling, and the largest pharmacy-compounding fight the peptide market has seen.
The recurring mistake is separating the ingredient from the product. A reviewed Ozempic, Wegovy, or Rybelsus package comes with a defined device or tablet, formulation, storage plan, label, and adverse-event system. A compounded vial, a semaglutide salt form, a research-use listing, or a counterfeit pen shares the name and little else.
How people talk about it online
The conversation is dominated by weight loss in practice: appetite, food noise, nausea, constipation, reflux, dose escalation, missed doses, stopping and restarting, plateaus, muscle loss, protein intake, insurance, telehealth access, shortages, and switching between GLP-1 drugs.
Compounded-product talk has its own vocabulary: custom doses, added B12, lower cost, multi-dose vials, oral or sublingual options, same active ingredient. FDA and survey sources answer each of those phrases with a product variable: concentration, dose device, formulation, storage, and quality controls.
Buying online adds a darker question: whether the contents match the label at all. Market surveillance has documented nondelivery scams and probable substandard or falsified products, so identity is a live question rather than a formality.
Use context
Routes, doses, and cycle patterns
Semaglutide schedule details only make sense after the product is named. The FDA-reviewed labels describe weekly injections and daily tablets with gradual escalation. Compounded and online-market sources describe a different problem: variable concentrations, measuring errors, added ingredients, salt forms, false labels, and weak storage disclosure. In that setting, "what dose?" is not enough; the product, concentration, and measuring device all have to be identified.
Human studies and product labels
Ozempic injection label
- Purpose
- Type 2 diabetes and related labeled risk-reduction use
- Context
- FDA label
- Route
- Subcutaneous injection
- Amount
- 0.25 mg once weekly for initiation; 0.5 mg, 1 mg, or 2 mg once weekly maintenance depending on label criteria
- Frequency
- Once weekly
- Duration
- Label describes chronic treatment rather than a short cycle
Ozempic is a diabetes product label. Its once-weekly injection schedule is not a dosing model for Wegovy, Rybelsus, compounded vials, or oral or sublingual products.
Wegovy injection label
- Purpose
- Chronic weight management and other Wegovy-labeled uses
- Context
- FDA label
- Route
- Subcutaneous injection
- Amount
- Starts at 0.25 mg weekly; escalates through 0.5 mg, 1 mg, and 1.7 mg; maintenance depends on indication
- Frequency
- Once weekly
- Duration
- Escalation occurs over 16 weeks before maintenance in the label schedule
The current Wegovy label lists indication-specific maintenance language, including 1.7 mg or 2.4 mg weekly for adult weight reduction and separate language for cardiovascular risk reduction, pediatric weight reduction, and noncirrhotic MASH with moderate to advanced liver fibrosis in adults.
Wegovy tablet label
- Purpose
- Adult cardiovascular risk reduction or weight reduction
- Context
- FDA label
- Route
- Oral tablet
- Amount
- 1.5 mg daily for 30 days, then 4 mg daily, then 9 mg daily, then 25 mg daily maintenance
- Frequency
- Once daily
- Duration
- Escalation over 90 days before maintenance in the label schedule
The tablet label is separate from the injectable schedule. Oral semaglutide tablet milligrams, injection milligrams, vial concentration, and syringe units are separate product facts.
Rybelsus and Ozempic tablet label
- Purpose
- Type 2 diabetes and cardiovascular-risk language in adults with type 2 diabetes
- Context
- FDA label
- Route
- Oral tablet
- Amount
- Oral tablet schedules are product-specific and come from the current label.
- Frequency
- Once daily
- Duration
- Label describes chronic diabetes treatment rather than a fixed short cycle
Rybelsus and Ozempic tablets share oral semaglutide tablet labeling but are not mg-for-mg substitutes. Their tablet schedules are not conversion tables for Ozempic injection, Wegovy injection, Wegovy tablets, or compounded vials.
GLP-1 shortage and compounding policy update
- Purpose
- Semaglutide injection shortage and compounder transition timing
- Context
- FDA policy page
- Route
- Injectable semaglutide products
- Amount
- Policy source; no dose
- Frequency
- Policy source; no frequency
- Duration
- FDA shortage-transition dates in April-May 2025; not a patient treatment duration
FDA said the semaglutide injection shortage was resolved and also said it may still act on other violations, including substandard quality or unsafe products.
Real-world discussion
Compounded and telehealth GLP-1 programs
- Purpose
- Weight loss and glycemic discussion
- Context
- Telehealth clinics, med-spas, and compounded-semaglutide programs
- Route
- Subcutaneous injection
- Amount
- Clinic programs commonly mirror the label-style weekly titration starting at 0.25 mg and increasing through 0.5, 1.0, and 1.7 mg toward 2.0 to 2.4 mg weekly. Compounded vials require per-vial concentration math, and FDA has documented dosing errors with compounded versions.
- Frequency
- Once weekly in nearly all clinic and community discussion
- Duration
- Open-ended chronic use in clinic framing, with community recomposition or maintenance phases sometimes describing lower-than-label weekly amounts
Real-world schedules largely borrow the approved label titration, but compounded products are not the approved drug, and concentration and measurement errors are a documented FDA concern. Community microdosing discussion is prevalent and unverified. Reported here as context, not as a recommendation.
Research-use and gray-market vial discussion
- Purpose
- Non-clinic weight-loss use
- Context
- Vendor listings and forum reports
- Route
- Subcutaneous injection from lyophilized vials
- Amount
- Vial amounts are mapped back to label-style weekly doses in community math, commonly in the 0.25 to 2.4 mg per week range
- Frequency
- Once weekly
- Duration
- Multi-month titration runs in community logs
Gray-market semaglutide is sold despite the molecule being on FDA warning letters aimed at online sellers. Identity, purity, and concentration are unverified, and the label titration these amounts imitate belongs to a different, approved product.
What varies
- Product: exact product identity determines claim interpretation because Ozempic, Wegovy, Rybelsus, compounded products, and online seller products differ in indication, dosage form, device, storage, and oversight.
- Route: weekly injection, daily oral tablet, sublingual marketing, and multi-dose vial use create different absorption and dose-measurement issues.
- Amount: injection milligrams, tablet milligrams, vial concentration, syringe units, and dose escalation belong to different product contexts.
- Indication: diabetes, chronic weight management, cardiovascular risk reduction, kidney risk reduction, MASH, and weight loss outside labeled indications are different claims.
- Quality: identity, sterility, endotoxin, concentration, degradation, storage, beyond-use date, and authenticity matter as much as the molecule name.
Human data
Human evidence
Few peptides have human evidence this deep: regulator-reviewed labels for three products, large phase 3 programs, and cardiovascular-outcome data behind them. Every part of it attaches to a specific product in a specific population. The characteristic semaglutide error is not doubting the evidence; it is lending that evidence to products it never covered: compounded vials, salt forms, online sellers, improvised titration. The trials are silent on all of those.
Evidence maturity
Semaglutide is the reference arc for the category: full development program, multiple approvals, then a compounding era FDA had to push back on.
Large phase 3 programs (STEP, SUSTAIN) across weight management and diabetes.
Ozempic, Wegovy, and Rybelsus approvals with regulator-reviewed labels.
Cardiovascular-outcome trial evidence added beyond weight and glucose endpoints.
Shortage-driven compounding, dosing-error reports, and FDA warnings.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Ozempic injection label | People with type 2 diabetes in Ozempic-labeled settings | FDA prescribing information | Approved product | The label supports type 2 diabetes claims, once-weekly injection dosing, GLP-1 mechanism, safety warnings, and Ozempic-specific formulation. | Ozempic labeling does not define every semaglutide product as a diabetes product, weight-management product, or equivalent injectable formulation. | Strong |
| Wegovy label | Wegovy-labeled adult and pediatric groups depending on indication | FDA prescribing information | Approved product | The label supports chronic weight-management dosing, adult cardiovascular risk-reduction language, pediatric weight-reduction language, and noncirrhotic MASH with moderate to advanced liver fibrosis in adults. | Wegovy data and dosing stay tied to Wegovy's studied products and label, not Ozempic, Rybelsus, compounded products, oral-disintegrating products, or research vials. | Strong |
| Rybelsus/Ozempic oral semaglutide tablet label | Adults with type 2 diabetes in oral semaglutide label settings | FDA prescribing information | Approved product | The label supports daily oral semaglutide tablet schedules for Rybelsus and Ozempic tablets and separates those tablet schedules from Ozempic injection, Wegovy injection, Wegovy tablets, and compounded-vial schedules. | Oral tablet schedules cannot be converted directly into injection schedules or compounded-vial schedules. | Strong |
| FDA compounded semaglutide dosing-error alert | Patients and health professionals exposed to compounded injectable semaglutide products | FDA safety communication | Compounded products | FDA described dosing errors tied to measurement, concentration, and unit conversion problems, with some adverse events requiring hospitalization. | The alert is a safety and product-use warning, not an efficacy comparison between approved and compounded products. | Moderate |
| Online semaglutide market surveillance | Online semaglutide sellers and products sold without a prescription | Market surveillance and product-quality analysis | Online seller and gray-market products | The study documented illegal-pharmacy traffic, nondelivery scams, probable substandard or falsified products, low-purity findings, and endotoxin concerns. | This is a product-quality and market-risk study, not a study of whether semaglutide works or fails in a medical population. | Moderate |
| Compounded semaglutide and tirzepatide product survey | Websites marketing compounded semaglutide or tirzepatide products | Product and website survey | Compounded and telehealth-market products | The survey found varied dosage forms, added ingredients, and limited beyond-use-date or storage disclosure. | Website descriptions may list dosage form or ingredients while leaving potency, sterility, and comparability to approved products unresolved. | Weak to moderate |
Cautions
Safety and unknowns
- Gastrointestinal adverse reactions dominate the label and patient conversation: nausea, vomiting, diarrhea, constipation, abdominal pain, reflux-type symptoms, and dehydration risk can drive dose pauses or discontinuation.
- Semaglutide labels carry thyroid C-cell tumor warning language and contraindications tied to personal or family history of medullary thyroid carcinoma or MEN2.
- Pancreatitis, gallbladder disease, acute kidney injury from volume depletion, hypoglycemia with insulin or insulin secretagogues, hypersensitivity, diabetic retinopathy complications, and delayed gastric emptying all matter when comparing products and patients.
- Delayed gastric emptying can affect oral medication timing and perioperative risk discussions; tablets also have administration conditions that do not apply to injections.
- Pregnancy, breastfeeding, pediatric use, kidney disease, liver disease, and cardiovascular risk vary by product and indication rather than a general semaglutide shortcut.
- Compounded products add separate risks: dose-measurement errors, different concentrations, salt forms, added ingredients, false labels, sterility, endotoxin, storage, and underreported adverse events.
Product quality
A vial label is only a starting point
Approved semaglutide products have named labels, strengths, devices or dosage forms, excipients, storage language, manufacturing controls, and adverse-event systems.
FDA says compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
FDA has warned about compounded injectable semaglutide dosing errors, salt forms such as semaglutide sodium or acetate, fraudulent compounded labels, and counterfeit Ozempic.
Published online semaglutide testing and compounded-product surveys show why website claims, low price, added ingredients, alternate dosage forms, and posted COAs are only one part of the quality picture.
Product identity
The label may say semaglutide, but the product might not match an FDA-reviewed active ingredient, formulation, dosage form, or supply chain.
Concentration and device
Pens, syringes, tablets, multi-dose vials, and oral or sublingual products create different dose-measurement and administration risks.
Sterility and endotoxin
Injectable products need microbial and endotoxin control; a purity percentage is only a chemistry number.
Storage and dating
GLP-1 peptides can be mishandled or degraded, and some compounded product websites disclose limited storage or beyond-use-date details.
Salt forms and added ingredients
FDA has raised concerns about semaglutide salt forms, and added ingredients can change tolerability and interpretation; better outcomes would need their own evidence.
Mechanism
How it is proposed to work
Semaglutide imitates GLP-1 signaling for longer than native GLP-1. In plain terms, it helps the body respond to high glucose with more insulin and less glucagon, slows early gastric emptying, and affects appetite pathways tied to calorie intake and body weight.
The Ozempic label describes semaglutide as a GLP-1 analog with 94% sequence homology to human GLP-1 that selectively binds and activates the GLP-1 receptor.
Albumin binding, lower renal clearance, protection from metabolic degradation, and stabilization against DPP-4 degradation support its long half-life and once-weekly injection products.
Mechanism is not product equivalence. A receptor agonist in a regulated pen or tablet comes with a different quality system than a compounded vial, salt form, or online seller product.
FAQ
Common questions
Is compounded semaglutide the same as Ozempic or Wegovy?
No. The approved products are regulator-reviewed finished drugs with verified concentration and devices. Compounded versions are not FDA-approved, and FDA has warned about dosing errors and salt-form differences with compounded semaglutide.
What does the approved dosing schedule look like?
The label starts at 0.25 mg once weekly and escalates roughly every four weeks, through 0.5, 1.0, and 1.7 mg, toward maintenance doses up to 2.4 mg weekly for weight management, adjusted by tolerability. Clinic and compounded programs commonly imitate this schedule.
Does semaglutide work for weight loss?
Yes, within its labeled context: large randomized trials showed substantial average weight loss versus placebo in the studied populations, which is why it carries FDA approvals for chronic weight management. Individual results vary, and the label includes a boxed thyroid C-cell warning plus gastrointestinal cautions.
Why is an approved drug on a peptide evidence site?
Because semaglutide is the anchor comparison for the entire metabolic category: it shows what regulator-reviewed evidence looks like, and it is the reference point for evaluating compounded, research-market, and next-generation incretin claims.
Details
Technical details
Sources
References
- 1.
Accessed 2026-06-08.
FDA distinguishes approved semaglutide products from compounded semaglutide products and describes dosing-error concerns.
- 2.
FDA. Compounding and the FDA: Questions and Answers 2026.
Accessed 2026-06-08.
FDA explains that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness, or quality before marketing.
- 3.
DailyMed. OZEMPIC (semaglutide) injection prescribing information 2026.
Accessed 2026-06-16.
Current DailyMed label source for Ozempic injection indications, once-weekly dosing, GLP-1 mechanism, warnings, and product formulation.
- 4.
DailyMed. WEGOVY (semaglutide) injection and tablet prescribing information 2026.
Accessed 2026-06-16.
Current DailyMed label source for Wegovy approved indications, injection titration, tablet titration, maintenance doses, warnings, and formulation details.
- 5.
DailyMed. RYBELSUS and OZEMPIC tablets (oral semaglutide) prescribing information 2026.
Accessed 2026-06-16.
Current DailyMed label source for oral semaglutide tablet strengths, initiation, escalation, switching language, indications, and warnings.
- 6.
FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize 2025.
Accessed 2026-06-16.
FDA policy source for semaglutide injection shortage resolution, transition dates for compounders, and continuing safety/quality enforcement.
- 7.
FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss 2026.
Accessed 2026-06-16.
FDA safety page covering fraudulent compounded semaglutide and tirzepatide, dosing errors, salt-form concerns, counterfeit Ozempic, and GLP-1 API concerns.
- 8.
PubMed. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription 2024.
PMID:39509151 Accessed 2026-06-16.
Online semaglutide market surveillance source documenting illegal-pharmacy traffic, nondelivery scams, low-purity findings, and endotoxin concerns.
- 9.
PubMed. Compounded Semaglutide and Tirzepatide Products Use Unique Ingredients and Dosage Forms 2026.
PMID:41689811 Accessed 2026-06-16.
Survey source for compounded semaglutide and tirzepatide products with varied dosage forms, added ingredients, and limited beyond-use-date or storage disclosure.